Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04792502 · ClinicalTrials.gov registry record · Phase 2
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
A Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Brown University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 3
- Study locations
NCT04792502 is a Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma that is actively recruiting participants, run by Brown University. The registered enrollment target is 52 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (61% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04792502, a Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma, is actively recruiting participants, sponsored by Brown University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients who achieve PR at IRA will receive mosunetuzumab with lenalidomide augmentation during C5-8. Primary response assessment (PRA) will occur after C8. Patients who remain in PR at PRA will continue for additional 4 cycles (extended augmentation).
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Lenalidomide
Study Locations (3)
Connecticut
- Yale Cancer Center - New Haven
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Rhode Island
- Lifespan Cancer Insitute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04792502
The ClinicalTrials.gov registry entry for NCT04792502 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (61% lower). The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Mosunetuzumab is the first listed.
NCT04792502 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, New Jersey, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT04792502 about?
NCT04792502 is a clinical study titled "Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma". BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 2...
What is the current status of trial NCT04792502?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2022-07-14. Estimated completion is 2027-08-31.
What conditions does trial NCT04792502 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma.
What interventions are being tested in trial NCT04792502?
The interventions under investigation include: Mosunetuzumab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT04792502?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04792502 being conducted?
This trial has 3 study locations across Connecticut, New Jersey, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.